LONDON, Nov. 17, 2020 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO1 and AUTO3 data presented at the American Society of Hematology (ASH) Virtual Congress 2020 and will also participate in the Jefferies Banking Conference:
About Autolus Therapeutics plc
Autolus is a clinical-stage biopharmaceutical company developing next-generation, programmed T cell therapies for the treatment of cancer. Using a broad suite of proprietary and modular T cell programming technologies, the company is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize cancer cells, break down their defense mechanisms and eliminate these cells. Autolus has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. For more information please visit www.autolus.com.
Contact:
Lucinda Crabtree, PhD
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
l.crabtree@autolus.com
Julia Wilson
+44 (0) 7818 430877
j.wilson@autolus.com
Susan A. Noonan
S.A. Noonan Communications
+1-212-966-3650
susan@sanoonan.com
Los Angeles, California--(Newsfile Corp. - June 3, 2025) - This National Cancer Survivor Month, St.…
TOKYO, June 3, 2025 /PRNewswire/ -- ThinkCyte, a life science company pioneering advanced AI-powered cell…
New open-source tool connects Healthie's GraphQL API to leading AI assistants via the Model Context…
SOMERVILLE, Mass., June 3, 2025 /PRNewswire/ -- Matterworks, Inc., the category-defining pioneer unlocking unstructured molecular…
DELRAY BEACH, Fla., June 3, 2025 /PRNewswire/ -- The global Digital Pathology Market, valued at US$1.29…
CARMEL, Ind., June 3, 2025 /PRNewswire/ -- In further commitment to increasing health care access…